The company is valued at < $50M now, if the cancer combo therapy is effective the company is still worth at least $100M, maybe much more if other indications too.
If they can assess 1/2 CX the patients by April 2017 and it fails to show any efficacy then they can minimize dilution if they cancel the trial and just focus on the cancer combo trials, which has minimal expenses.
News 
Market Data 
Discover 
